Breast - British Journal of Surgery

Scientific Surgery

Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor–positive breast cancer: long-term follow-up of the BIG 1-98 Trial. J Clin Oncol 2019; 37: 105-114.

Authors: Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen M-B, Ejlertson B, de Azambuja E et al.

Scientific Surgery

Six versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019; 393: 2599–2612.

Authors: Earl HM, Hiller L, Vallier A-L, Loi S, McAdam K, Hughes-Davies L et al.

Scientific Surgery

Six months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 2019; 393: 2591-2598.

Authors: Pivot X, Romieu G, Debled M, Pierga J-Y, Kerbrat P, Bachelot T et al.

Scientific Surgery

Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH Phase 3 randomized clinical trial. JAMA Oncol 2019; 5:e190339.

Authors: Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC et al.

Scientific Surgery

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019; 393: 1440-1452.

Authors: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

Scientific Surgery

Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380: 617-628.

Authors: Von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M et al.

Scientific Surgery

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 2018; 19: 1385-1393.

Authors: Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M et al.

Scientific Surgery

Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial. J Clin Oncol 2018; 36: 3126-3133.

Authors: Bardia A, Parton M, Kummel S, Estevez LG, Huang C-S, Cortes J et al.

Scientific Surgery

Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node–positive and high-risk lymph node–negative breast cancer (E5103). J Clin Oncol 2018; 36: 2621-2629.

Authors: Miller KD, O’Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA et al.

Scientific Surgery

Prospective randomized trial of use of in-house prepared low-cost radiopharmaceutical versus commercial radiopharmaceutical for sentinel lymph node biopsy in patients with early stage invasive breast cancer. World J Surg 2018; 42: 1391-1395.

Authors: Agarwal G, Rajan S, Mayilvaganan S, Mishra A, Krishnani N, Gambhir S et al.

Scientific Surgery

Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018; 379:122-137.

Authors: Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I et al.

Scientific Surgery

Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018; 379:111-121.

Authors: Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF et al.

Scientific Surgery

Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst 2018; 110: 40-48.

Authors: Blok EJ, Kroep JR, Kranenbarg EM-K, Duijm-de Carpentier M, Putter H, van den Bosch J et al.

Scientific Surgery

De-escalation strategies in human epidermal growth factor receptor 2 (HER2)–positive early breast cancer (BC): final analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial optimizing risk assessment and therapy response prediction in early BC HER2- and hormone receptor–positive phase II randomized trial—efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET. J Clin Oncol 2017; 35: 3046-3054.

Authors: Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S et al.

Scientific Surgery

Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. J Clin Oncol 2017; 35: 2639-2646.

Authors: Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen M-B, Knoop AS, Højris I et al.

Scientific Surgery

Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla – Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. EJSO 2017; 43: 672-679.

Authors: Sávolt A, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E et al.

Scientific Surgery

Intraoperative ultrasound guidance in breast-conserving surgery shows superiority in oncological outcome, long-term cosmetic and patient-reported outcomes: Final outcomes of a randomized controlled trial (COBALT). EJSO 2017; 43: 649-657.

Authors: Volders JH, Haloua MH, Krekel NMA, Negenborn VL, Kolk RHE, Lopes Cardozo AMF et al.

Scientific Surgery

Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis. The ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 2017; 318: 918-926.

Authors: Giuliano AG, Ballman KV, McCall L, Beitsch P, Brennan MB, Keleman PR et al.

Older Entries

Newer Entries